Replimune announces RP2 development program advances

Replimune (REPL) Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naive metastatic uveal melanoma; and second-line recurrent or metastatic hepatocellular carcinoma. “On the heels of our BLA submission for RP1 and designation as breakthrough therapy, we are pleased that the first patients have been enrolled in both the RP2 HCC clinical trial and the registration intended study of RP2 in metastatic uveal melanoma,” said Sushil Patel, Ph.D., CEO of Replimune. “We are excited to explore the broader potential of the RPx platform and these RP2 clinical trials will play an important part of our future development plans.”